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Abstract
Purpose: The purpose of this study is to assess the feasibility of conducting a large, multicentre randomised
controlled trial (RCT) comparing needle fasciotomy with limited fasciectomy for treatment of Dupuytren’s
contractures.
Design: The design of this study is a parallel, two-arm, multicentre, randomised feasibility trial with embedded
QuinteT Recruitment Intervention.
Participants: Patients aged 18 years or over who were referred from primary to secondary care for treatment of a
hand with Dupuytren’s contractures of one or more fingers of more than 30° at the metacarpophalangeal (MCP)
and/or proximal interphalangeal (PIP) joints and well-defined cord(s). Patients were excluded if they had undergone
previous Dupuytren’s contracture surgery on the same hand.
Methods: Potential participants were screened for eligibility. Recruited participants randomised (1:1) to treatment
with either needle fasciotomy or limited fasciectomy and followed-up for up to 6 months after treatment. Data on
recruitment rates, completion of follow-up, and procedure costs were collected. Four patient reported outcome
measures (PROMs) and objective outcome measures were collected before intervention and 6 weeks and 6 months
afterwards.
Results: One hundred and fifty-three of 267 (57%) primary-care referrals for Dupuytren’s contractures met the
eligibility criteria for the study. Seventy-one of the 153 (46%) agreed to participate and were randomly allocated to
treatment with needle fasciotomy or limited fasciectomy. Sixty-seven of these underwent their allocated treatment,
two were crossovers from limited fasciectomy to needle fasciotomy, and two (both allocated limited fasciectomy)
received no treatment. Fifty-nine participants (85%) completed 6-month follow-up PROMs. Participants felt the
MYMOP, PEM and URAM PROMs allowed them to better describe how their treatment affected their hand function
than the DASH PROM. The estimated costs of limited fasciectomy (in an operating theatre) and needle fasciotomy
(in a clinic room) were £777 and £111 respectively.
Conclusion: A large RCT comparing treatment of Dupuytren’s contractures by needle fasciotomy and limited
fasciectomy is feasible. Data from this study will help determine the number of sites and duration of recruitment
required to complete an adequately powered RCT and will assist the selection of PROMs in future studies on the
treatment of Dupuytren’s contractures. (Level 1 feasibility study).
Trial registration: Trial registered with ISRCTN (registration number: ISRCTN11164292), date assigned - 28/08/2015.
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Introduction
Needle fasciotomy (NF) and limited fasciectomy (LF)
are established surgical treatments offered to patients
with Dupuytren’s contractures of the fingers. NF can
be undertaken in a clinic room and has a short re-
covery period, whereas LF is performed in an operat-
ing theatre and has a longer recovery period. A
systematic review of surgery for Dupuytren’s contrac-
ture [1] found one small randomised controlled trial
(RCT) comparing these treatments, which showed
that LF corrects contractures better [2] and has a
lower recurrence contracture rate [3] than NF. How-
ever, NF is cheaper than LF, carries a lower risk of
complications and can be successfully repeated [4].
The systematic review also highlighted that the pri-
mary outcome of most existing studies is based on
angular deformity of the finger joints. Though popu-
lar with health professionals, this is not a good surro-
gate for hand function as it does not consider the
impact of treatment complications, such as finger
numbness, loss of flexion and pain, on hand function
[1]. Patient-centred studies, which assess function
using appropriate, relevant Patient-Reported Outcome
Measures (PROMs), are required to guide day-to-day
clinical practice.
It is not known which of NF and LF preserves hand
function better and is more cost-effective in the long
term, and a large, multicentre RCT is needed to address
these uncertainties. However, there is insufficient infor-
mation available to effectively plan a multi-centre RCT
of LF versus NF. A feasibility study which “asks whether
something can be done, should we proceed with it, and if
so, how?” is therefore needed [5]. The overall aim of the
present study was to investigate the feasibility of con-
ducting an RCT comparing NF with LF. This paper pre-
sents data regarding patient eligibility, recruitment and
retention rates, and the performance of potential
primary and secondary endpoints for clinical and cost-
effectiveness. A QuinteT Recruitment Intervention
(QRI) [6] to identify difficulties and optimise the recruit-
ment process was embedded within the study and quali-
tative interviews were undertaken to explore patient
experience. These are reported separately (Husbands S,
Elliott D, Davis T, Blazeby J, Harrison E, Montgomery
A, et al.: Optimising recruitment to the HAND-1 RCT
feasibility study: integration of the QuinteT Recruitment
Intervention (QRI), submitted to Pilot Feasibility Stud
2019).
Methods
The trial was registered prior to the start of recruitment
(ISRCTN11164292, 28 August 2015). The protocol pro-
vides details of the study design and methods [7]. There-
fore, the methods are only briefly described here.
Trial design, eligibility criteria, setting and location
This was a parallel, two-arm, three centre, randomised
controlled feasibility trial. The inclusion criteria were
aged 18 years or over; one or more fingers with a DC of
more than 30° in the metacarpophalangeal (MCP) and/
or proximal interphalangeal (PIP) joints; well-defined
cord(s) causing contracture; no previous DC surgery on
the same hand. The exclusion criteria were DC of the
distal interphalangeal (DIP) joint only; planned dermo-
fasciectomy or very limited fasciectomy (excision of a 1
cm or smaller cord segment); previous recruitment into
this study; life expectancy less than 3 years. Recruitment
took place in Hand Surgery clinics in three secondary
care sites in England: Derby Teaching Hospitals NHS
Foundation Trust, Wrightington, Wigan and Leigh NHS
Foundation Trust and Nottingham University Hospitals
NHS Trust/Nottingham Treatment Centre.
Participant screening, recruitment and consent
Between November 2015 and September 2016, NHS pa-
tients referred to Hand Clinics at the three sites were
assessed for eligibility to the trial. At one hospital, refer-
ral letters were screened by the site principal investigator
to direct patients who appeared to satisfy the eligibility
criteria to “recruiting clinics” where they could be in-
vited to participate in the study. In the second hospital,
referral letters were not screened and potential partici-
pants were not guided to recruiting clinics. In the third,
all GP referrals with Dupuytren’s contractures were in-
vited to opt into this study by volunteering to attend a
research clinic.
Before their clinic appointment, patients were sent an
information leaflet about the study. At the appointment,
the treating clinician assessed patients for study eligibil-
ity, explained the study to eligible patients, and invited
them to participate. Those who were interested in par-
ticipating were seen by a researcher at the same clinic
appointment, written informed consent was given, and
the participant was randomised. Potential participants
who wished to have more time to consider joining the
study were offered another clinic appointment for con-
sent and randomisation. The reasons why eligible pa-
tients chose not to participate were recorded.
Interventions
Following randomisation, participants were placed on
the waiting list for their allocated treatment. NF was per-
formed in a clinic room with a hypodermic needle (21G:
green or 23G: blue) using minimal local anaesthetic. LF
was performed in an operating theatre under general or
regional anaesthetic, using the surgeon’s favoured skin
incision. For contractures involving the MCP joint, the
cord was excised proximally to at least the proximal
margin of the transverse fibres of the palmar
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aponeurosis. Digital cords were excised completely from
their origin. In all cases, the distal margin of the cord ex-
cision was the insertion of the cord onto the flexor ten-
don sheath (or other structure).
Outcomes
Feasibility outcomes were:
1) Recruitment: Number of participants assessed for
eligibility, number and proportion of those assessed
who were eligible, reasons for non-eligibility, num-
ber and proportion of patients randomised;
2) Retention: number and proportion of randomised
participants attending 6 week and 6-month post-
treatment follow-up visits and reasons for non-
attendance;
3) Identification of primary and secondary outcomes
for a multicentre RCT.
Four Patient-Reported Outcome Measures (PROMs)
were assessed as potential primary outcome measures
for a definitive RCT. These were the Unité Rhumato-
logique des Affections de la Main (URAM) [8],
Disabilities of the Arm, Shoulder and Hand Question-
naire (DASH) [9]; Part 2 (10 questions) of the Patient
Evaluation Measure (PEM) [10] and the Measure
Yourself Medical Outcome Profile (MYMOP) [11, 12].
The MYMOP is a generic, patient-generated (indivi-
dualised) outcome questionnaire which is brief and
simple to administer. It is symptom and activity-
specific but includes general wellbeing [13, 14]. Par-
ticipants completed the four PROMS at the recruit-
ment clinic before randomisation, and at 2 weeks, 6
weeks and 6 months post-treatment. The PEM was
also completed on the day of treatment to monitor
for change in status between recruitment and treat-
ment, whilst on the NHS waiting list. The PROMs
were assessed to determine their appropriateness for
use as the primary outcome measure in a definitive
RCT by: (a) recording completion rates at each time
point; (b) asking each participant at each time point
to record for each PROM how relevant it was to how
their hand looked, felt and worked at that time on a
five-point Likert scale (strongly agree, agree, neither
agree nor disagree, disagree, strongly disagree) and;
(c) calculation of the minimally clinical important dif-
ference (MCID).
Other outcomes collected included:
a. Global Rating of Change Scale (GRC) at 6 months
[15]. This acted as the anchor for the assessment of
the performance of the PROMs and calculation of
their MCIDs;
b. Angular measurement of MCP and PIP
contractures (hand-held goniometer) at baseline, 6
weeks and 6 months;
c. Complications of treatment (i.e. nerve or tendon
injury, finger stiffness, complex regional pain
syndrome);
d. Adverse events. This was limited to three serious
adverse events: death due to any cause, loss of
finger due to any cause and any unexpected serious
events potentially related to the intervention.
e. Health-related quality of life as measured by the
generic EQ-5D-5 L questionnaire [16];
f. Return to work and NHS resource use;
g. A micro-costing of the two procedures.
The only change made to the trial assessments or out-
comes during the conduct of the trial was to bring for-
ward the 6-month questionnaire completion of
participants recruited within the final 6 months before
the study closed.
Sample size
As this was a feasibility study, a sample size calculation
based on power to detect a pre-specified between-group
difference in a primary outcome was not appropriate.
We aimed for a target sample size of 50–85 based on
the assumption that three centres would assess 600 pa-
tients with Dupuytren’s contractures during the recruit-
ment period, of whom 400 (67%) would be eligible and
invited to participate, and that 13–21% of invited pa-
tients would consent and be randomised. This would en-
able estimation of recruitment fraction for a future study
to within 5 percentage points (margin of error = half-
width of 95% confidence interval), and within 14
percentage points for binary outcomes assessed among
randomised participants.
Randomisation
Participants were randomised (1:1) to treatment with ei-
ther NF or LF using a secure internet-based system. This
was maintained by the Nottingham Clinical Trials Unit
(NCTU) in accordance with their standard operating
procedures. No one directly involved in the study had
access to the allocation codes. Randomisation was strati-
fied by the recruiting centre and by the joints affected
(MCP only, PIP only or MCP+PIP), and used computer-
generated, permuted balanced blocks of randomly
varying size. Blinding of the surgeons, researchers per-
forming the clinical assessments and participants to
intervention allocation was not possible.
Statistical methods
We used appropriate descriptive statistics to describe re-
cruitment data, baseline characteristics of participants,
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compliance with allocated intervention, completeness of
data collection, and outcomes at follow-up. The statis-
tical analysis plan was finalised before database lock and
release of treatment codes to the statistician.
Participants’ opinions of the PROMs were used to
guide the choice of which to use as the primary outcome
in a future definitive trial. We planned to estimate the
MCID and responsiveness using effect size for each of
the four PROMs using the GRC as the “anchor” [17].
However, neither was possible because an insufficient
number of participants (n = 7) reported feeling a “little
better” on the GRC.
Formal between-group comparison of outcomes is not
appropriate in a feasibility study [18]. We, therefore,
present data by treatment group using only descriptive
statistics.
Costing methods
We used a combination of information collected on the
trial case report form and clinical opinion to provide
cost data for the two procedures. The case report form
included details of the duration of each procedure (from
introduction of anaesthetic until the patient left the pro-
cedure room), anaesthetic type (general, regional, local),
surgeon(s) (consultant and/or trainee), splint provision
and length of stay (admission date until discharge date).
We used clinical opinion to estimate the other operating
room staff, the consumables, and reusable equipment re-
quired for the NF and LF procedures. The unit cost (in
2017) of each resource was obtained from the hospital
finance departments at either the Nottingham University
Hospitals or the Nottingham Treatment Centre. Staff
costs were estimated using NHS ‘agenda for change’ pay
rates or, for consultants, per session rates. For both pro-
cedures, we included overhead costs at 30% to account
for shared hospital costs (e.g. administration and
utilities).
Results
Recruitment
Of 267 primary care referrals with a primary (not a recur-
rent) Dupuytren’s contracture who were screened, 153
(57%) were eligible (Fig. 1). The most common reasons for
ineligibility were previous Dupuytren’s surgery to another
finger of the same hand and a contracture of 30° or less.
Other exclusion criteria were infrequent and “life expect-
ancy less than 3 years” was difficult to determine. Only
seven cases were excluded as the surgeon considered them
unsuitable for treatment by either NF or LF. Seventy-one
of the 153 (46%) eligible patients consented to be rando-
mised to treatment with NF or LF. Of the 82 patients who
were eligible but not randomised, 75 preferred a specific
treatment, of which 48 opted for NF. The remaining seven
opted for no treatment (Fig. 1). Baseline demographic
characteristics and PROM data were balanced between
the two treatment arms (Table 1).
Patients with involvement of MCP joint only, PIP
joint only and both MCP and PIP joints were recruited
at all three centres, showing willingness of surgeons to
recruit patients with each of these different DC patterns
(Table 1).
Compliance with allocated treatment
Sixty-seven patients received their allocated treatment.
Two patients randomised to LF received NF due to pref-
erences and another two did not receive surgery before
the study closed (Fig. 1).
Retention and follow-up
There were delays between randomisation and treatment
due to NHS waiting lists for surgery: median 97 days for
LF and 41 days for NF. As follow-up was timed from the
treatment rather than randomisation, this resulted in 10
of the 69 participants who received their treatment not
attending a 6-month clinic follow-up by the end of the
study. Nine of these participants returned questionnaires
sent by post earlier than 6months (the earliest was 20
weeks after treatment).
Sixty-three (91%) of the 69 treated participants
attended their 6-week follow-up appointment and 50
(85%) of the 59 who could have attended their 6-month
follow-up before the study closed did so. On average,
the timing of follow-up closely matched the planned
schedule at 2 and 6 weeks and 6months (Additional file
1: Table S1).
Outcome completion
Data collected on the day of surgery was over 90%
complete. This detailed the duration of surgery and hos-
pital stay, surgeon status (consultant/trainee), the precise
surgery performed, recognition of any immediate surgi-
cal complications (i.e. nerve injury), and the immediate
effect of the intervention on contracture.
Data on hand grip strength and angular measurement
of persistent finger deformity at 6 weeks were complete
in over 88% of the 69 treated participants and over 80%
of the 50 participants who could have attended the 6-
month post-surgery assessment clinics.
Over the whole follow-up period of the study, 753 of
887 PROMs (85%) were completed sufficiently for ana-
lysis (Additional file 2: Table S2).
On the day of surgery, the PEM was completed suf-
ficiently for evaluation in 60 (87%) of the 69 treated
participants. The 2-week post-surgery PROMS, which
were posted to participants for completion at home,
were returned by 61 (88%) of the 69 treated partici-
pants and each of the four individual PROMs was
evaluable in 75% or more instances. At the 6-week
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post-surgery assessments, the PROMs were completed
in clinic, and were completed sufficiently for evalu-
ation in 85% or more instances. At 6 month follow-
up, when 50 of the 59 participants completed the
PROMs in the clinic and nine by post, the comple-
tion rate was again at least 85%.
Fig. 1 Flowchart reporting numbers of patients assessed for eligibility and recruited and randomised, and numbers of participants followed up at
each timepoint
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PROM assessment
Forty-six (78%) of 58 participants who completed the
GRC at 6 months reported feeling “much better”, seven
(12%) “a little better”, one (2%) “unchanged” and four
(7%) “a little worse”. Mean scores were improved for
each of the four PROMS at 6 months among participants
reporting improvement on the GRC (Table 2).
Table 3 shows the change from baseline for each
PROM at 6 weeks and 6months. Summary PROM data
at baseline and follow-up by treatment arm are shown in
Table 4.
A high proportion of participants reported the
PROMS as relevant to their hand condition at baseline
and follow up (Additional file 3: Table S3). The DASH
had lower reported relevance than the other PROMS at
baseline and 2 weeks.
The mean PEM score increased slightly in both the
NF (2.9: SD = 11.5, N = 33) and LF (3.3: SD = 7.1, N =
26) groups between baseline and the day of treatment,
whilst waiting for treatment.
Correlations between changes from baseline to 6
months in the four PROM scores and changes in angular
measurement (using a goniometer) of the treated finger
were weak (DASH 0.387, PEM 0.382) to moderate
(MYMop 0.598, URAM 0.507).
Table 1 Demographic and clinical characteristics at baseline
Needle
fasciotomy
(n = 38)
Limited
fasciectomy
(n = 33)
Age (years)
Mean[SD] 66.9 [7.1] 64.4 [7.8]
Gender
Male 27 (71%) 27 (82%)
Female 11 (29%) 6 (18%)
Ethnicity
White 38 (100%) 33 (100%)
Right or left handed
Right 30 (79%) 27 (82%)
Left 8 (21%) 5 (15%)
Missing 0 (0%) 1 (3%)
Study hand
Right 19 (50%) 22 (67%)
Left 19 (50%) 11 (33%)
Dominant hand affected 17 (45%) 18 (54%)
Study finger
Index 0 0
Little 20 (53%) 21 (64%)
Middle 5 (13%) 4 (12%)
Ring 13 (34%) 8 (24%)
Joints affected on study finger
MCP joint only 12 (32%) 10 (30%)
PIP joint only 12 (32%) 10 (30%)
MCP and PIP joints 14 (37%) 13 (39%)
Grip strength for trial hand (kgf), mean[SD] 28.2 [12.3] 30 [11.1]
Grip strength for non-trial hand (kgf),
mean[SD]
30.5 [10.9] 32.6 [10]
Extension angular measurement (degrees),
mean [SD]
MCP joint 43.4 [19] 47.3 [19.9]
PIP joint 45.4 [17.1] 44.8 [20.4]
DIP joint 25.4 [25.3] 34.3 [18.2]
DASH score, mean[SD] 20.3 [19.4] 20.9 [15.3]
PEM score, mean[SD] 27.2 [13.8] 29.8 [12.3]
URAM score, mean[SD] 19.5 [11] 21.3 [11.6]
MYMOP profile score, mean[SD] 3.1 [1.1] 3.3 [1.3]
EQ-5D-5 L score, mean[SD] 0.808
[0.200]
0.813
[0.175]
All data are N (%)’s unless specified
SD Standard deviation
Table 2 Change from baseline score at 6 months for each of
the PROMS according to self-reported global assessment of
change at 6 months post-surgery
GRC at 6 months
Worse or about
the same
GRC at 6 months
A little better or
much better
DASH (possible range 0–100)
Mean (SD) 6.5 [9.9] −13.8 [16.8]
Median (25th, 75th centile) 6.2 [−2.1, 15] −11.7[−17.9, −3.7]
Min, max −2.5, 15.8 −60, 42.5
N 4 52
PEM (possible range 0–70)
Mean (SD) 8.8 [3.8] −19.0[14.0]
Median (25th, 75th centile) 8 [7, 11] −18[−30, −11]
Min, max 4, 14 −55, −26
N 5 51
URAM (possible range 0–45)
Mean (SD) 2.0 [1.4] −16.7 [11.4]
Median (25th, 75th centile) 1.5 [1, 3] −16.5 [−26, −8]
Min, max 1, 4 −40,8
N 4 50
MYMOP (possible range 0–6)
Mean (SD) −0.1 [1.2] −2.3 [1.2]
Median (25th, 75th centile) 0.3 [−1.2, 0.6] −2.3 [−3, −1.6]
Min, max −1.5, 1.3 −5.7, 0
N 5 53
For all four PROMS, a lower score indicates a greater improvement
from baseline.
SD Standard deviation
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Correction of finger deformity
Fifty-two of the 60 MCP joint contractures were fully
corrected by treatment (LF or NF). Twenty-two of 47
contractures of the PIP joint were fully corrected. The
median residual proximal interphalangeal joint contrac-
ture was 20°. Summary data for correction of deformity
and grip strength at baseline and follow-up by treatment
arm are shown in Table 5.
Complications of surgery
These are summarised in Table 6. Complications
were uncommon, but not negligible and a larger
study would be needed to compare between the
treatments.
Serious adverse events
There was only one serious adverse event which was the
unrelated death of one participant. No safety concerns
were identified.
Costs and resource use
The mean (SD) procedure times were 88.2 (23) and 19.4
(9) minutes for LF and NF respectively, a difference of
68.7 minutes (95% CI 60.3 to 77.1). Most (72%) of LF
procedures were performed using a regional block
anaesthetic. Most patients (83%) who had LF were pre-
scribed a finger splint compared to the minority of pa-
tients (32%) who had NF. The estimated total cost of the
LF procedure, excluding the costs of a pre-operative as-
sessment, finger splints and time spent in the recovery
room and on the day case ward, was £777 (Table 7).
One patient who had LF required a two-night stay in
hospital which would have incurred additional costs.
The estimated total cost of the NF procedure was £111
(Table 8).
One patient had a limited fasciectomy in the 6 months
following the initial needle fasciotomy. This patient also
visited the ED with wound dehiscence approximately 10
days after the limited fasciectomy. A further two patients
had a carpal tunnel release in the 6 months following the
initial procedure. About one third of patients were work-
ing at all time points after the procedure (Table 9). In
those who were working, mean time lost from work in
the last 7 days due to hand/finger problems decreased
after the procedure; no time was lost from work in the
last 7 days at 6 months post-procedure.
Discussion
This study has confirmed important aspects of feasibility
required for the design and conduct of a future rando-
mised trial to compare needle fasciotomy with limited
fasciectomy for treating Dupuytren’s contractures. We
successfully identified, screened, invited and randomised
eligible patients from three sites, and about half of eli-
gible patients agreed to participate. Most participants re-
ceived their treatment as allocated and completed clinic
visits or questionnaires at up to 6-month follow-up. We
found that patient-reported outcome measures were re-
sponsive to change but were not particularly strongly as-
sociated with improvements in the extension of treated
finger joints, an outcome that is often used clinically to
measure treatment success. A definitive trial in patients
with Dupuytren’s contracture assessing the clinical and
cost-effectiveness of NF and LF in terms of patient-
reported outcomes is therefore feasible and acceptable in
the UK and recommended to inform clinical decision-
making and health policy.
Table 3 Summary of PROMs change from baseline at 6 weeks
and 6months for all participants
Change from baseline
Mean [SD]
Median [25th, 75th Centile]
At 6 weeks At 6 months
DASH −7.7 [14.8] −12.4 [17.2]
−7.5 [−16.4, −1.7] −9.6 [−17.5, −2.9]
PEM −14.8 [15.2] −16.5 [15.6]
−15 [−26, −8] −17.5 [−28, −7.5]
URAM −13.6 [12.1] −15.3 [12.1]
−13 [−22, −5] −13 [−25, −7]
MYMOP profile score −2 [1.2] −2.1 [1.4]
−2[−3, −1.2] −2.2 [−3, −1.5]
SD standard deviation
Table 4 Summary of PROM scores by allocated group, at baseline and 6 months
Baseline 6 months
Needle fasciotomy
N = 38
Limited fasciectomy
n = 33
Needle fasciotomy
N = 33
Limited fasciectomy
n = 26
DASH, mean[SD] 20.3 [19.4] 20.9 [15.3] 9.3 [16.2] 7.0 [7.9]
PEM, mean[SD] 27.2 [13.8] 29.8 [12.3] 10.8 [15.4] 13.3 [14.5]
URAM, mean[SD] 19.5 [11] 21.3 [11.6] 4.8 [6.7] 4.2 [6]
MYMOP profile score, mean[SD] 3.1 [1.1] 3.3 [1.3] 1.1 [1.3] 1.0 [1]
EQ5D-5 L, mean[SD] 0.808 [0.200] 0.813 [0.175] 0.915 [0.145] 0.881 [0.181]
SD Standard deviation
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We recognise that 6-month follow-up is insufficient to
investigate recurrence rates following treatment, which
are known to increase with length of follow-up and dif-
fer markedly for NF and LF [3]. Recurrence affects hand
function, the need for further treatment and cost, and
follow-up of at least 5 years would be desirable for a de-
finitive trial comparing these two treatments.
Our feasibility findings relate to three sites, and may not
be easily generalisable to all centres where Dupuytren’s con-
tractures are treated. This is because patient pathways,
length of waiting lists and the enthusiasm of surgeons to
randomise patients to either NF or LF will vary from centre
to centre. Some centres may be reluctant to recruit patients
with contractures of the proximal interphalangeal joint as
Table 5 Summary of clinical outcomes by allocated group, at baseline and 6months
Baseline 6 months
Needle fasciotomy
N = 38
Limited fasciectomy
n = 33
Needle fasciotomy
N = 30
Limited fasciectomy
n = 20
Grip strength for trial hand (kgf)
Mean[SD] 28.2 [12.3] 30 [11.1] 30.4 [13.1] 28 [9.4]
Grip strength for non-trial hand (kgf)
Mean[SD] 30.5 [10.9] 32.6 [10] 30.9 [11.2] 37.6 [8.6]
Extension angular measurement (degrees)
MCP joint Mean[SD] 43.4 [19] 47.3 [19.9] 3.8 [5.9] 2.4 [5.4]
PIP joint Mean[SD] 45.4 [17.1] 44.8 [20.4] 20.3 [19.8] 15.5 [19.2]
DIP joint Mean[SD] 25.4 [25.3] 34.3 [18.2] 3.1 [8] 4.8 [12.4]
SD Standard deviation
Table 6 Summary of complications following treatment
NF group
(N = 38)
LF group
(N = 33)
6 weeks post-surgery
Delayed wound healing 0 2
Numbness 1 2
Loss of flexion in operated finger 1 1
Loss of flexion in one or more fingers 2 3
Complete division of flexor tendon 0 0
Complex regional pain syndrome 0 0
Other complication 1 1
6 months post-surgery
Delayed wound healing 0 0
Numbness 3 0
Loss of flexion in operated finger 2 4
Loss of flexion in one or more fingers 2 3
Complete division of flexor tendon 0 0
Complex regional pain syndrome 0 0
Loss of finger 0 0
Other complication 4 1
Data are number of participants with complications. Numbness was not
quantified and does not necessarily indicate a digital nerve injury
Table 7 Micro-costing of LF procedure
Limited fasciectomy (88-minute procedure)
Resource £
Staffing costs
Consultant anaesthesiologist £192.50
Operating Department Assistant £24.13
Theatre (scrub) nurses (×2) £45.46
Theatre (runner) nurse £26.82
Theatre auxiliary £14.58
Consultant surgeon £192.50
Registrar (in 45% of cases) £19.56
Sub-total £515.55
Consumable costs
Tourniquet (disposable cuff) £9.90
Eschmark exsanguination bandage £1.68
Disposable light handles £0.42
Scalpel blades £2.32
4-0 vicryl rapide suture (2 packets) £3.80
Gelanite £0.37
Melanite £0.33
3-inch plaster wool £3.54
50 cm 3-inch plaster £1.94
Elastoplast 15 cm £1.09
Bradford sling £14.53
Reusable equipment*
Lead hand and 5 elastic bands (reusable) £4.43
Black handled scissors £4.43
Orthopaedic tray £33.24
Sub-total £82.02
Overhead cost (@30%) £179.27
Total cost £776.85
* As these items are re-used frequently we assumed that the capital cost per
patient was negligible. These costs reflect the washing and sterilisation costs
between procedures
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they do not consider NF appropriate in this situation. This
is because of concerns it may cause nerve damage, even
though the reported rate of this complication is low [19, 20]
and a systematic review reports greater rates of nerve injury
after limited fasciectomy [21]. Also, the stipulation to per-
form NF in a clinic room setting, rather than an operating
theatre, may be resisted by some centres due to the idiosyn-
crasies of NHS reimbursement, in which £1085 is paid for a
NF in an operating theatre, and only £73 for one in a clinic
room. For these reasons, an embedded QuinteT Recruit-
ment Intervention, as used in this trial, is advised within the
definitive trial to identify and address site-specific barriers to
recruitment in each recruiting site (Husbands S, Elliott D,
Davis T, Blazeby J, Harrison E, Montgomery A, et al.: Opti-
mising recruitment to the HAND-1 RCT feasibility study:
integration of the QuinteT Recruitment Intervention (QRI),
submitted to Pilot Feasibility Stud 2019).
Three of the four PROMS (MYMOP, PEM and
URAM) were consistently considered relevant by partici-
pants. All could be used as the potential primary
outcome for the definitive multicentre RCT. The
MYMOP is not used widely, if at all, in hand surgery,
whereas the PEM and URAM are widely used. The
URAM was designed specifically for Dupuytren’s surgery
and considers losses in function expected in association
with the inability to fully straighten the fingers and does
not assess pain or strength. The PEM is not disease-
specific, assesses hand function more generally, and in-
cludes assessments of pain and strength. It is also the
primary outcome in an ongoing multicentre study com-
paring the treatment of Dupuytren’s contractures by
limited fasciectomy and collagenase injection (goo.gl/
zhvyq8).
Despite participants in the LF group having a longer
wait between randomisation and treatment than those
allocated to NF, reflecting usual NHS care, we found
similar mean changes in PEM scores during this period
in both groups. This suggests follow-up from the day of
treatment, rather than baseline, is acceptable for studies
of Dupuytren’s contracture treatment, and that the lon-
ger delay between randomisation and treatment with LF,
rather than NF, would not bias the results of a RCT
comparing these two treatment options.
The health economics questionnaire allowed deter-
mination of time off work for those participants who
were in employment. Clinic room and operating theatre
costs for NF and LF were also estimated. Not surpris-
ingly, there is a considerable difference between the
costs of these two treatments. The calculated cost of
needle fasciotomy is similar to the cost calculated in an-
other study [22].
The use of questionnaires to measure both clinical and
health economic outcomes potentially allows remote
follow-up of participants, without the need for research
clinic attendances after standard clinical follow-up is
complete. Remote collection of data beyond 3months
after treatment would reflect NHS care, as most patients
have been discharged from follow-up clinics by this
stage. It might also increase participant retention rate.
Whilst we achieved 80% follow-up at a 6-month re-
search clinic attendance, remote follow-up might im-
prove retention, particularly at longer follow-up and for
participants who may have difficulty attending clinics.
However, an objective assessment of participants in the
early follow-up phase would ensure complications are
detected and quantified. A 6-week clinical follow-up ap-
pointment would be suitable, and our findings suggest
Table 8 Micro-costing of NF procedure
Needle fasciotomy (18-minute procedure)
Resource £
Staffing costs
Procedure room nurse—band 5 £4.65
Consultant surgeon £39.38
Registrar (in 45% of cases) £4.00
Sub-total £48.02
Consumable costs
2-ml syringe £0.63
23-gauge (blue)hypodermic needle £0.56
25-gauge (orange) hypodermic needle £0.56
21-gauge (green) hypodermic needle £0.56
Dressing pack £0.31
Sterile drapes £0.32
Dressings £3.90
Alcoholic chlorhexidine £14.10
5 ml 1% lidocaine £16.10
Non-sterile clinic room blue gloves £0.06
Sub-total £37.10
Overhead cost (@30%) £25.54
Total cost £110.66
Table 9 Employment status and hours lost from work in the last 7 days, complete case analysis (n = 46)
Timepoint Currently working for pay (%) Mean (SD) hours lost, among workers
2 Weeks 16/46 (35) 10.75 (16.3)
6 Weeks 17/46 (37) 4.35 (10.3)
6 Months 15/46 (33) 0 (0)
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that numbness needs to be quantified to distinguish sig-
nificant digital nerve injuries from less significant dimin-
ished sensibility. Also, the frequency and severity of
recurrent contracture formation at later follow-up times
is an important secondary outcome measure. A simple
and reliable method for assessing finger straightness
which can be undertaken by participants in their homes
is needed if this is to be assessed remotely. Potential
methods include digital photography and simple
goniometers.
Our data assists the planning of a future multicentre
RCT comparing NF with LF. It has highlighted: (a) is-
sues with the eligibility criteria which can be improved
(i.e. changing "contracture of more than 30°” to "contrac-
ture of 30° or more” and “life expectancy of less than 3
years: to “likely to be available to complete follow-up”)
and; (b) shown that recruitment would be enhanced by
modification to allow recruitment of patients who had
previously had treatment for a Dupuytren’s contracture
of another finger in the same hand. However, their pre-
vious experiences of treatment may make them reluctant
to agree to recruitment, consent and randomisation.
Conclusions
A large RCT comparing treatment of DC by NF and LF
is feasible. We would recommend the number of recruit-
ing sites and duration of such a study is determined on
the basis of: (a) about 50% of referrals from primary care
being eligible; (b) about 50% of those eligible being will-
ing to be recruited and randomised to treatment and; (c)
a 6-month retention rate of about 85%. Delays in
provision in treatment, particularly for LF, also need to
be considered to ensure the follow-up phase of the study
is sufficiently long. Participants felt the MYMOP, PEM
and URAM PROMs allowed them to better describe the
condition of their hand than the DASH.
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